Purchase this article with an account.
Y. Hirano, T. Ito, M. Nozaki, M. Yoshida, Y. Ogura; Incidence and Risk Factors of Intraocular Pressure Elevation After Triamcinolone Acetonide Administration for Macular Disorders . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3418.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the incidence and risk factors of intraocular pressure (IOP) elevation following triamcinolone acetonide (TA) administration for macular disorders.
Intravitreal or posterior sub–Tenon’s injection of TA was performed on 202 patients (224 eyes) with diffuse diabetic macular edema (66 eyes), branch retinal vein occlusion (39 eyes), central retinal vein occlusion (25 eyes), exudative age–related macular degeneration (49 eyes), myopic choroidal neovascularization (10 eyes), uveitis (30 eyes) and other reasons (5 eyes). Simultaneous intravitreal and sub Tenon’s injection was performed on 85 eyes. Mean follow–up after TA administration was 15.9.±10.4 (range 3–39) months. Risk factors for IOP elevation were analyzed. We studied the effect of following factors, history of vitrectomy, route of administration, frequencies of injection, refractive error and age of the patients.
IOP readings higher than 21, 30, 40 and 50 mmHg were measured in 82 eyes (37 %), 35 eyes (16 %), 12 eyes (5.4 %) and 2 eyes (0.9 %). Fifty seven eyes (25 %) were treated by antiglaucoma medication. Two eyes (0.9 %) required trabeculotomy to control the IOP. Risk factors for the IOP elevation included younger age (P=0.026), high myopia (P=0.013) and multiple injections (0.038).
These findings may be useful for comparing risks and benefits of TAtherapy. Careful follow–up of the IOP is required after TA injections.
This PDF is available to Subscribers Only